Show simple item record

AuthorHussain, Arif
AuthorHasan, Anwarul
AuthorNejadi Babadaei, Mohammad Mahdi
AuthorBloukh, Samir Haj
AuthorChowdhury, Muhammad E.H.
AuthorSharifi, Majid
AuthorHaghighat, Setareh
AuthorFalahati, Mojtaba
Available date2020-08-23T07:51:27Z
Publication Date2020-10-01
Publication NameBiomedicine and Pharmacotherapy
Identifierhttp://dx.doi.org/10.1016/j.biopha.2020.110559
Citationprotein A. Hussain, et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomedicine & Pharmacotherapy 130 (2020) 110559
ISSN07533322
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088960686&origin=inward
URIhttp://hdl.handle.net/10576/15755
AbstractThe Authors As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site. Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230, 80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of interaction of RBD and different mAbs were explained and it was suggested that one of the SARS-CoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARS-CoV2 S-protein RBD. Finally, some ongoing challenges and future prospects for rapid and sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In conclusion, it may be proposed that this review may pave the way for recognition of RBD and different mAbs to develop potential therapeutic ESV.
Languageen
PublisherElsevier
Subjectantibodies
Corona virus
epitope-specific vaccines (ESV)
receptor binding domain
spike protein
TitleTargeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies
TypeArticle
Volume Number130
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record